newsfilter
← Latest News
GlobeNewswire·

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Taysha Gene Therapies, Inc. announced on November 6, 2026, that its Compensation Committee granted two new employees 25,000 restricted stock units (RSUs) representing common stock on November 2, 2026.
  • The RSUs were issued under the 2023 Inducement Plan to comply with Nasdaq Listing Rule 5635(c)(4).
  • Vesting for the RSUs will occur in four equal annual installments starting on the first anniversary of the vesting commencement date, contingent on continued employment.
  • Taysha is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases.
  • The company's lead program, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder lacking approved disease-modifying therapies.
Company
Taysha Gene Therapies, Inc.
Keywords
Nasdaq:TSHA, Taysha Gene Therapies, Inc.